<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="article-commentary">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">SRdQqWwTD9M3pHkL6WbxJkc</article-id>
      <article-id pub-id-type="other">00018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2011000400018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(11)09600418</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2011000400018</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Endocardite mar&#226;ntica e adenocarcinoma de s&#237;tio prim&#225;rio oculto</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Schlittler</surname>
            <given-names>Luis Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dallagasperina</surname>
            <given-names>Viviane Weiller</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schavinski</surname>
            <given-names>Claudia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baggio</surname>
            <given-names>Ana Paula</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lazaretti</surname>
            <given-names>N&#237;colas Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Villaroel</surname>
            <given-names>Rodrigo Ughini</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Passo Fundo</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Hospital da Cidade</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2011</year>
      </pub-date>
      <volume>96</volume>
      <issue>4</issue>
      <fpage>e73</fpage>
      <lpage>e75</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <pub-date publication-format="electronic" date-type="pub">
        <day>02</day>
        <month>05</month>
        <year>2011</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>
      <bold>Endocardite mar&#226;ntica e adenocarcinoma de s&#237;tio prim&#225;rio oculto</bold>
    </p>
    <p>
      <bold>Luis Alberto Schlittler; Viviane Weiller Dallagasperina; Claudia Schavinski; Ana Paula Baggio; N&#237;colas Silva Lazaretti; Rodrigo Ughini Villaroel</bold>
    </p>
    <p>Hospital da Cidade de Passo Fundo, Passo Fundo, RS - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p><bold>Palavras-chave: </bold>Endocardite, embolia e trombose, acidente cerebral vascular, adenocarcinoma, p&#226;ncreas.</p>
    <p>A endocardite tromb&#243;tica n&#227;o bacteriana &#233; caracterizada pela deposi&#231;&#227;o de trombos e fibrina sobre valvas card&#237;acas normais ou degeneradas na aus&#234;ncia de germes. A patologia est&#225; relacionada a estados inflamat&#243;rios cr&#244;nicos, com maior incid&#234;ncia de fen&#244;menos emb&#243;licos quando comparada &#224; endocardite infecciosa. Os autores relatam o caso de um paciente masculino, 63 anos, com adenocarcinoma de s&#237;tio prim&#225;rio oculto e embolia sist&#234;mica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Em 1865, Trousseau exp&#244;s a associa&#231;&#227;o entre c&#226;ncer e tromboembolismo<sup>1</sup>. Em 1988, Ziegler descreveu a endocardite tromb&#243;tica n&#227;o bacteriana (ETNB) como deposi&#231;&#227;o de trombos e fibrina sobre valvas card&#237;acas. Estudos posteriores identificaram a rela&#231;&#227;o entre ETNB e estados inflamat&#243;rios cr&#244;nicos, incluindo malignidades, septicemia e queimaduras extensas<sup>2</sup>.</p>
    <p>Os n&#237;veis elevados do fator de necrose tumoral e interleucina 1, presentes no c&#226;ncer, podem causar dano ao endot&#233;lio valvar e forma&#231;&#227;o de trombos<sup>3</sup>.</p>
    <p>A incid&#234;ncia de fen&#244;menos emb&#243;licos &#233; maior que a observada na endocardite infecciosa<sup>2</sup>. Al&#233;m disso, o quadro cl&#237;nico &#233; decorrente do s&#237;tio de embolia, sendo incomum o achado de um novo sopro card&#237;aco.</p>
    <p>O diagn&#243;stico &#233; constitu&#237;do pela visibiliza&#231;&#227;o de uma vegeta&#231;&#227;o endoc&#225;rdica associada &#224; aus&#234;ncia de germes vi&#225;veis no sangue<sup>2</sup>.</p>
    <p>O manejo da ETNB consiste no tratamento da malignidade subjacente associado &#224; anticoagula&#231;&#227;o sist&#234;mica<sup>4</sup>.</p>
    <p>Os autores relatam o caso de um paciente com adenocarcinoma de s&#237;tio prim&#225;rio oculto que desenvolveu sintomas neurol&#243;gicos associados &#224; embolia perif&#233;rica. Na avalia&#231;&#227;o da origem dos &#234;mbolos, diagnosticou-se ETNB.</p>
    <p>
      <bold>Relato do caso</bold>
    </p>
    <p>Paciente masculino, 63 anos, relatou dor epig&#225;strica em aperto h&#225; seis meses, exacerbada h&#225; quatro dias, acompanhada de n&#225;useas, v&#244;mitos e emagrecimento de dez quilos nos &#250;ltimos dois meses. O paciente era alccolista e realizou cirurgia para implanta&#231;&#227;o de pr&#243;tese total de quadril h&#225; tr&#234;s meses sem intercorr&#234;ncias.</p>
    <p>Ao exame, apresentava-se em bom estado geral, l&#250;cido, afebril, ict&#233;rico +/4+, extremidades bem perfundidas. Exame abdominal: espa&#231;o de traube ocupado, borda hep&#225;tica palp&#225;vel na regi&#227;o epig&#225;strica, cinco cent&#237;metros abaixo do rebordo costal direito, com consist&#234;ncia endurecida e dolorosa, ba&#231;o n&#227;o palp&#225;vel. Ao exame card&#237;aco: Ictus palp&#225;vel no 5&#186; espa&#231;o intercostal, linha hemiclavicular, 1,5 cm, bulhas normofon&#233;ticas, ritmo regular em dois tempos, sem sopros. Demais sistemas sem altera&#231;&#245;es.</p>
    <p><italic>Laborat&#243;rio -</italic> Hemoglobina 11,9 g/dl; hemat&#243;crito 37,1%; VCM 84,13fL; CHCM 32,08; plaquetas 500.000/mm<sup>3</sup>; leuc&#243;citos totais 15200/mm<sup>3</sup> com 35% de neutr&#243;filos 1% de bast&#245;es; Prote&#237;na C reativa&lt; 7; sedimento urin&#225;rio: bilirrubina (+); gama glutamil transferase 128U/l; fosfatase alcalina 145 U/l; bilirrubina total 0,91 mg%; bilirrubina direta 0,58 mg%; desidrogenase l&#225;tica 719 U/l; demais exames laboratoriais sem altera&#231;&#245;es.</p>
    <p><italic>Ultrassonografia de abdome -</italic> les&#227;o expansiva no lobo hep&#225;tico esquerdo, hipoecoide, heterog&#234;nea, com 12,3 cm no seu maior di&#226;metro. Demais &#243;rg&#227;os com aspecto normal.</p>
    <p><italic>Tomografia computadorizada (TC) de abdome total -</italic> Ascite de pequeno volume, forma&#231;&#227;o expansiva macrolobulada, de limites imprecisos no lobo hep&#225;tico esquerdo, envolvendo os segmentos II, III e IV, a qual apresenta-se hipodensa, impregnando-se heterogeneamente pelo contraste. Lobo hep&#225;tico direito com volume diminu&#237;do, contornos bocelados e densidade parenquimatosa heterog&#234;nea, al&#233;m de m&#250;ltiplas pequenas &#225;reas hipodensas, esparsas no par&#234;nquima. Trombo intraluminal estendendo-se da veia femoral direita at&#233; a veia cava inferior. Demais estruturas sem altera&#231;&#245;es.</p>
    <p>Foi institu&#237;da anticoagula&#231;&#227;o plena com heparina n&#227;o fracionada associada &#224; varfarina.</p>
    <p><italic>Bi&#243;psia hep&#225;tica -</italic> par&#234;nquima hep&#225;tico infiltrado por tecido neopl&#225;sico, constitu&#237;do por &#225;cinos glandulares, revestidos por c&#233;lulas c&#250;bicas e cil&#237;ndricas, com c&#233;lulas em anel de sinete. Na an&#225;lise imuno-histoqu&#237;mica apresentou reatividade para anti-CK7 e anti-CEA. N&#227;o houve positividade para anti-CK20, anti-CDX2, anti-TTF1, anti-CA19.9 e anti-Heppar. Conclui-se tratar de adenocarcinoma de s&#237;tio prim&#225;rio oculto.</p>
    <p>No terceiro dia de interna&#231;&#227;o o paciente passou a apresentar desorienta&#231;&#227;o e agressividade alternados com per&#237;odos de lucidez.</p>
    <p><italic>TC de cr&#226;nio -</italic> les&#245;es hipodensas difusas, sem realce pelo contraste, localizadas na subst&#226;ncia branca, adjacentes aos cornos dos ventr&#237;culos laterais, redu&#231;&#227;o volum&#233;trica encef&#225;lica global.</p>
    <p>No quadrag&#233;simo dia de interna&#231;&#227;o o paciente desenvolveu cianose tanto na por&#231;&#227;o distal do membro inferior direito, quanto nos dedos da m&#227;o direita, com diminui&#231;&#227;o da temperatura local (<xref ref-type="fig" rid="f1">Figura 1</xref>). Devido &#224; ocorr&#234;ncia deste quadro na vig&#234;ncia de anticoagula&#231;&#227;o plena, o tratamento foi mantido.</p>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf01.jpg"/></fig>
    <p>Foi realizado Doppler-ecocardiograma transtor&#225;cico uni e bidimensional, que evidenciou valva a&#243;rtica espessada com estrutura ecog&#234;nica m&#243;vel, de 11 mm, compat&#237;vel com vegeta&#231;&#227;o, importante fluxo regurgitante nesta valva, regurgita&#231;&#227;o mitral leve, disfun&#231;&#227;o ventricular esquerda segmentar de grau moderado; o paciente apresentou tamb&#233;m disfun&#231;&#227;o diast&#243;lica ventricular esquerda padr&#227;o restritivo e dilata&#231;&#227;o de c&#226;maras card&#237;acas (<xref ref-type="fig" rid="f2">Figura 2</xref>).</p>
    <fig id="f2">
      <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf02.jpg"/></fig>
    <p>Ap&#243;s o ecocardiograma, institui-se tratamento com gentamicina e ampicilina. Foram realizadas seis coletas de sangue para hemocultura automatizada com o aparelho Bactec, em s&#237;tios diferentes. N&#227;o houve desenvolvimento de germes em cinco dias de cultura.</p>
    <p>O paciente n&#227;o apresentou melhora com a antibioticoterapia, tendo apresentado necrose das extremidades, concomitante ao desenvolvimento de fal&#234;ncia ventilat&#243;ria, e evoluindo, assim, para &#243;bito.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A endocardite tromb&#243;tica n&#227;o bacteriana, anteriormente nomeada endocardite mar&#226;ntica, &#233; caracterizada pela deposi&#231;&#227;o de trombos em valvas card&#237;acas e aus&#234;ncia de bact&#233;rias vi&#225;veis na corrente sangu&#237;nea<sup>2</sup>.</p>
    <p>A incid&#234;ncia &#233; desconhecida. Uma s&#233;rie de aut&#243;psias revelou 10 casos em 1.640 adultos, preval&#234;ncia de 1,25% nos pacientes com c&#226;ncer e 0,2% na popula&#231;&#227;o geral. Pacientes com adenocarcinoma, principalmente adenocarcinoma de p&#226;ncreas, tiveram uma preval&#234;ncia maior<sup>4</sup>. Autores relatam que as malignidades mais associadas com ETNB s&#227;o os tumores de pulm&#227;o, p&#226;ncreas, est&#244;mago e adenocarcinoma de s&#237;tio prim&#225;rio desconhecido<sup>2</sup>.</p>
    <p>A ETNB &#233; mais comum entre a quarta e oitava d&#233;cadas de vida e n&#227;o h&#225; predile&#231;&#227;o por g&#234;nero. A incid&#234;ncia de embolia sist&#234;mica varia de 14% a 91%<sup>4,5</sup>.</p>
    <p>Os s&#237;tios mais frequentes de embolia arterial s&#227;o o ba&#231;o, o rim e extremidades, por&#233;m, embolia cerebral e coronariana alertam para o seu diagn&#243;stico, devido &#224; maior morbidade e mortalidade que causam. Al&#233;m disso o d&#233;ficit neurol&#243;gico s&#250;bito e focal &#233; a manifesta&#231;&#227;o cl&#237;nica mais comum<sup>2</sup>.</p>
    <p>Quando presentes, sopros card&#237;acos s&#227;o sist&#243;licos e com maior intensidade na borda esternal esquerda<sup>2</sup>.</p>
    <p>H&#225; embolia pulmonar em 50% dos casos, por&#233;m todos foram observados em pacientes com neoplasias avan&#231;adas e trombofilia sist&#234;mica concomitante &#224; ETNB<sup>6</sup>.</p>
    <p>Ecocardiografia transesof&#225;gica &#233; o m&#233;todo mais sens&#237;vel para o diagn&#243;stico de vegeta&#231;&#245;es<sup>6</sup>.</p>
    <p>As valvas mais afetadas em ordem decrescente s&#227;o: valva a&#243;rtica, valva mitral e o acometimento simult&#226;neo da valva a&#243;rtica e mitral. As vegeta&#231;&#245;es localizam-se na superf&#237;cie de coapta&#231;&#227;o dos folhetos, na face atrial das valvas mitral e tric&#250;spide e na face ventricular das valvas a&#243;rtica e pulmonar, em geral sem prejudicar a fun&#231;&#227;o valvar<sup>2,4</sup>.</p>
    <p>Alguns estudos sugerem sinergia entre a les&#227;o valvar, trombocitose e atividade dos fatores de coagula&#231;&#227;o<sup>2</sup>. An&#225;lises gen&#233;ticas evidenciaram que o oncogene MET causa aumento da atividade do inibidor do fator ativador do plasminog&#234;nio tipo 1 (PAI-1) e dos genes da cicloxigenase 2 (cox 2), contribuindo para a forma&#231;&#227;o de trombos<sup>7</sup>.</p>
    <p>A distin&#231;&#227;o entre endocardite tromb&#243;tica e infecciosa pode tornar-se um dilema diagn&#243;stico. Vegeta&#231;&#245;es na superf&#237;cie de coapta&#231;&#227;o sem destrui&#231;&#227;o do tecido valvar e o acometimento de valvas em sentido bilateral ou apenas do lado direito do cora&#231;&#227;o s&#227;o altamente sugestivos de ETNB<sup>5,8</sup>. Na resson&#226;ncia magn&#233;tica por difus&#227;o &#233; poss&#237;vel demonstrar que pacientes com ETNB tendem a desenvolver m&#250;ltiplos infartos no sistema nervoso central, amplamente distribu&#237;dos, enquanto les&#245;es &#250;nicas ou infartos focais s&#227;o mais caracter&#237;sticos da endocardite infecciosa<sup>2,5,8,9</sup>. No presente caso, embora sem comprova&#231;&#227;o histopatol&#243;gica, a aus&#234;ncia de febre, a negatividade persistente das hemoculturas e a aus&#234;ncia de melhora cl&#237;nica com a antibioticoterapia sugerem evid&#234;ncias fortes de ETNB.</p>
    <p>Pacientes com c&#226;ncer que desenvolvem sintomas neurol&#243;gicos devem ser avaliados, sendo a resson&#226;ncia magn&#233;tica nuclear o exame com maior sensibilidade para o diagn&#243;stico de met&#225;stases e acidentes vasculares encef&#225;licos. Al&#233;m disso, a resson&#226;ncia magn&#233;tica por difus&#227;o &#233; capaz de diferenciar se a origem do &#234;mbolo est&#225; ligada &#224; endocardite bacteriana ou &#224; ETNB<sup>9</sup>.</p>
    <p>O manejo da ETNB consiste no tratamento da malignidade subjacente e anticoagula&#231;&#227;o sist&#234;mica. O anticoagulante mais efetivo &#233; a heparina n&#227;o fracionada, com redu&#231;&#227;o da recorr&#234;ncia de tromboembolismo quando usada de forma cont&#237;nua<sup>10</sup>. Fen&#244;menos tromboemb&#243;licos recorrentes foram observados com o uso de antagonistas da vitamina K, mas essa associa&#231;&#227;o necessita de maiores estudos para confirma&#231;&#227;o<sup>2</sup>.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Viviane Weiller Dallagasperina </p>
        <p> Av. Aspirante Jenner 987 - Lucas Ara&#250;jo </p>
        <p> 99074-360 - Passo Fundo, RS - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="vividallagasperina@hotmail.com">vividallagasperina@hotmail.com</email>, </p>
        <p>
          <email xlink:href="vividallagasperina@bol.com.br">vividallagasperina@bol.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 18/07/09; revisado recebido em 09/12/09; aceito em 24/02/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Trousseau A.    Clinique medicale de l'Ho^tel- Dieu de Paris. 2nd Ed. Paris: Ballie're; 1865.    p. 654-712.</mixed-citation>
        <element-citation publication-type="book">
          <source>Clinique medicale de l'Ho^tel- Dieu de Paris</source>
          <date>
            <year>1865</year>
          </date>
          <fpage>654</fpage>
          <lpage>712</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Trousseau</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Shami K, Griffiths    E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis,    diagnosis, and treatment. The Oncologist. 2007; 12: 518-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment</article-title>
          <source>The Oncologist</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>518</fpage>
          <lpage>23</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shami</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Streiff</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Nakanishi K,    Tajima F, Nakata Y, Osada H, Ogata K, Kawai T, et al. Tissue factor is associated    with the nonbacterial thrombotic endocarditis induced by a hypobaric hypoxic    environment in rats. Virchows Arch.1998; 433: 375-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tissue factor is associated with the nonbacterial thrombotic endocarditis induced by a hypobaric hypoxic environment in rats</article-title>
          <source>Virchows Arch</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>375</fpage>
          <lpage>9</lpage>
          <volume>433</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nakanishi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tajima</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nakata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Osada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ogata</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Gonzalez Quintela    A, Candela MJ, Vidal C, Rom&#225;n J, Aramburo P. Non-bacterial thrombotic    endocarditis in cancer patients. Acta Cardiol. 1991; 46: 1-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Non-bacterial thrombotic endocarditis in cancer patients</article-title>
          <source>Acta Cardiol</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez Quintela</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Candela</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Vidal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rom&#225;n</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aramburo</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Amaral G, Santos    EH, Azevedo LCP, Azevedo LAP, Pimenta J. Endocardite tromb&#243;tica n&#227;o-bacteriana.    Arq Bras Cardiol. 1997; 68 (5): 373-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endocardite tromb&#243;tica n&#227;o-bacteriana</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>373</fpage>
          <lpage>5</lpage>
          <issue>5</issue>
          <volume>68</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Amaral</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>LCP</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>LAP</given-names>
            </name>
            <name>
              <surname>Pimenta</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Joffe II, Jacobs    LE, Owen AN, Ioli A, Kotler MN. Noninfective valvular masses: review of the    literature with emphasis on imaging techniques and management. Am Heart J. 1996;    131: 1175-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Noninfective valvular masses: review of the literature with emphasis on imaging techniques and management</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1175</fpage>
          <lpage>83</lpage>
          <volume>131</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Joffe</surname>
              <given-names>II</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Ioli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kotler</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Boccaccio C,    Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene    drives a genetic programme linking cancer to haemostasis. Nature. 2005; 434:    396-400.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The MET oncogene drives a genetic programme linking cancer to haemostasis</article-title>
          <source>Nature</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>396</fpage>
          <lpage>400</lpage>
          <volume>434</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Boccaccio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sabatino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Medico</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Girolami</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Follenzi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reato</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Borowski A,    Ghodsizad A, Cohnen M, Gams E. Recurrent embolism in the course of marantic    endocarditis. Ann Thorac Surg. 2005; 79: 2145-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recurrent embolism in the course of marantic endocarditis</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2145</fpage>
          <lpage>7</lpage>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Borowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ghodsizad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cohnen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gams</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Singhal AB,    Topcuoglu MA, Buonanno FS. Acute ischemic stroke patterns in infective and nonbacterial    thrombotic endocarditis: a diffusionweighted magnetic resonance imaging study.    Stroke. 2002; 33: 1267-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute ischemic stroke patterns in infective and nonbacterial thrombotic endocarditis: a diffusionweighted magnetic resonance imaging study</article-title>
          <source>Stroke</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1267</fpage>
          <lpage>73</lpage>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Singhal</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Topcuoglu</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Buonanno</surname>
              <given-names>FS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Salem DN, Stein    PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy    in valvular heart disease-native and prosthetic: the Seventh ACCP Conference    on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 457S-482S.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy</article-title>
          <source>Chest</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>457S</fpage>
          <lpage>482S</lpage>
          <volume>126</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Salem</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Al-Ahmad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bussey</surname>
              <given-names>HI</given-names>
            </name>
            <name>
              <surname>Horstkotte</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Marantic endocarditis and adenocarcinoma of unknown primary site</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Marantic endocarditis and adenocarcinoma of unknown primary site</bold>
          </label>
          <p>
            <bold>Luis Alberto Schlittler; Viviane Weiller Dallagasperina; Claudia Schavinski; Ana Paula Baggio; N&#237;colas Silva Lazaretti; Rodrigo Ughini Villaroel</bold>
          </p>
        </fn>
      </p>
      <p>Hospital da Cidade de Passo Fundo, Passo Fundo, RS - Brazil</p>
      <p>Mailing address</p>
      <p><bold>Keywords:</bold>Stroke, embolism, adenocarcinoma, endocarditis, pancreas.</p>
      <p>Nonbacterial thrombotic endocarditis (NBTE) is a disease characterized by deposition of thrombi and fibrin on normal or degenerated cardiac valves in the absence of microorganisms. This condition is more commonly seen in chronic inflammatory states, and is associated with higher incidence of thromboembolic events than infective endocarditis. We report the case of a 63-year old male patient with adenocarcinoma of unknown primary site and systemic embolism.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>In 1865, Trousseau described the association between cancer and thromboembolism<sup>1</sup>. In 1988, Ziegler described nonbacterial thrombotic endocarditis (NBTE) as the deposition of thrombi and fibrin on cardiac valves. Later studies have identified the relationship between NBTE and chronic inflammatory states, including malignancies, septicemia, and severe burns<sup>2</sup>.</p>
      <p>The elevated levels of tumor necrosis factor and interleukin-1, associated with cancer, may damage the valvular endothelium leading to thrombus formation<sup>3</sup>.</p>
      <p>The incidence of embolic phenomena is higher than that found in infective endocarditis<sup>2</sup>. In addition, clinical manifestations of NBTE result from systemic emboli, and the presence of a new cardiac murmur is a rare finding.</p>
      <p>The diagnosis of nonbacterial thrombotic endocarditis is based on visualization of endocardial vegetation associated with the absence of viable microorganisms in the bloodstream<sup>2</sup>.</p>
      <p>The standard of care for management of NBTE consists of treatment of the underlying malignancy and systemic anticoagulation<sup>4</sup>.</p>
      <p>The authors report the case of 63-year old male patient with adenocarcinoma of unknown primary site who developed neurological symptoms associated with peripheral emboli. NBTE was diagnosed after discovering the origin of the emboli.</p>
      <p>
        <bold>Case report</bold>
      </p>
      <p>A 63-year-old male patient complained of dull epigastric pain lasting six months that had worsened over the past four days, accompanied by nausea, vomiting, and weight loss of 20 pounds over the previous two months. The patient was an alcoholic, and three months before had undergone an uneventful total hip replacement.</p>
      <p>On physical examination, he was in good general condition, alert, afebrile and with well-perfused extremities but jaundiced (+/4+). Abdominal examination: Traube's space was obliterated, the liver edge was palpable in the epigastrium, 5 cm below the right costal margin, and was hard and tender; the spleen was not palpable. Cardiac examination: The apical impulse was palpable at the fifth intercostal space, 1.5 cm of the midclavicular line; his heart rate and rhythm were regular, with normal S1 and S2, and there were no murmurs. No changes were found in other organ systems.</p>
      <p><italic>Laboratory testes -</italic> Laboratory findings were as follows: Hemoglobin 11.9 g/dl; hematocrit 37.1%; MCV 84.13 fL; MCHC 32.08; platelet count 500,000/mm<sup>3</sup>; WBC count 15,200/mm<sup>3</sup>, with 35% of neutrophils and 1% of band forms, C-reactive protein &lt; 7. Urinalysis: bilirubin (+); gamma-glutamyltransferase 128 U/l; alkaline phosphatase 145 U/l; total bilirubin 0.91 mg/dl; conjugated bilirubin 0.58 mg/dl; lactic dehydrogenase 719 U/l. The other laboratory tests were unremarkable.</p>
      <p><italic>Abdominal ultrasonography -</italic> An abdominal ultrasound examination revealed a heterogeneous, hypoechoic, mass lesion in the left liver lobe measuring 12.3 cm in its largest diameter. The remaining organs appeared normal.</p>
      <p><italic>Abdominal computed tomography -</italic> A CT scan of the whole abdomen showed small-volume ascites and a macrolobutated, ill-defined, low-density, and heterogeneously-enhanced mass involving segments II, III and IV of the left liver lobe. The right liver lobe was decreased in size, with scalloped borders and heterogeneous density, in addition to multiple small low-density areas scattered in the liver parenchyma. A thrombus was found extending from the right femoral vein to the inferior vena cava. No changes were found in any of the other structures.</p>
      <p>Full anticoagulation therapy was initiated with unfractionated heparin and warfarin.</p>
      <p><italic>Liver biopsy -</italic> Histological examination of the liver revealed neoplastic tissue consisting of glandular acini lined with cubical and cylindrical cells, with signet-ring cells. Immunohistochemical stains were positive for anti-CK7 and anti-CEA, but negative for CK20, anti-CDX2, anti-TTF1, anti-CA19.9, and anti-Heppar. Therefore, a diagnosis of adenocarcinoma of unknown primary site was made.</p>
      <p>As of the third day of admission the patient began alternating periods of disorientation and aggressiveness with periods of lucidity.</p>
      <p><italic>Brain computed tomography -</italic> A CT brain scan revealed diffuse, low-density, non-enhanced lesions in the white matter adjacent to the horns of the lateral ventricles, in addition to global reduction in brain volume.</p>
      <p>On the fortieth day of admission, he developed cyanosis of the distal right lower extremity and the fingers of his right hand, with decreased local temperature (<xref ref-type="fig" rid="f1-body2">Figure 1</xref>). Because this condition occurred during full anticoagulation, drug treatment was maintained.</p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf01-en.jpg"/></fig>
      <p>Transthoracic Doppler echocardiography, using M-mode and two-dimensional imaging, revealed the following: a thickened aortic valve with a mobile, echogenic structure measuring 11 cm, consistent with vegetation; significant aortic regurgitation; mild mitral regurgitation; moderate segmental left ventricular dysfunction; left ventricular diastolic dysfunction of a restrictive pattern; and dilated cardiac chambers (<xref ref-type="fig" rid="f2-body2">Figure 2</xref>).</p>
      <fig id="f2-body2">
        <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf02-en.jpg"/></fig>
      <p>After the echocardiogram, the patient was treated with gentamicin and ampicillin. Six blood samples were taken from different sites and incubated in an automated Bactec blood culture system. No growth was observed after five days of incubation.</p>
      <p>The patient did not respond to antibiotic therapy. He developed necrosis of the extremities, together with ventilatory failure, and finally died.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Nonbacterial thrombotic endocarditis (NBTE), previously known as marantic endocarditis, is characterized by the deposition of thrombi on heart valves in the absence of viable circulating microorganisms<sup>2</sup>.</p>
      <p>The incidence of NBTE remains unknown. In a series of autopsy studies of 1640 adult patients, there were 10 cases of NBTE, with prevalence of 1.25% in cancer patients and 0.2% in the general population. The disease was more prevalent in patients with adenocarcinoma, especially pancreatic adenocarcinoma<sup>4</sup>. It has been reported that the most common malignancies associated with NBTE are cancers of the lung, pancreas and stomach and adenocarcinoma of unknown primary site<sup>2</sup>. The incidence of systemic embolism ranges from 14% to 91%<sup>4,5</sup>.</p>
      <p>NBTE is more common between the fourth and eighth decades of life and has no sex predilection.</p>
      <p>The most frequent sites of embolization are the spleen, kidney, and extremities, but cerebral and coronary embolism should alert to the diagnosis of NBTE, since they are the main cause of morbidity. In addition, the most common clinical manifestation of NBTE is a sudden, focal neurological deficit<sup>2</sup>.</p>
      <p>When present, heart murmurs are systolic and best heard at the left sternal border<sup>2</sup>.</p>
      <p>Pulmonary embolism affects 50% of the cases, but all of them were observed in patients with advanced neoplasias and systemic thrombophilia in the setting of NBTE<sup>6</sup>. Transesophageal echocardiography (TEE) is the most sensitive method for detecting vegetations<sup>6</sup>.</p>
      <p>The most commonly affected valves, in descending order of frequency, are: the aortic valve, the mitral valve, and combined aortic and mitral involvement. Vegetations are commonly found at the coaptation surface of the valve leaflets, on the atrial surfaces of the mitral and tricuspid valves and on the ventricular surfaces of the aortic and pulmonic valves, usually without impairing valve function<sup>2,4</sup>.</p>
      <p>Some studies suggest a synergy between the valvular injury, thrombocytosis, and coagulation factor activity<sup>2</sup>. Genetic studies have shown that the MET oncogene increases the activity of type-1 plasminogen activator inhibitor (PAI-1) and cyclooxygenase-2 (COX-2) genes, contributing to thrombus formation<sup>7</sup>.</p>
      <p>The differentiation between thrombotic and infective endocarditis can become a diagnostic dilemma. The presence of vegetations on the coaptation surface without destruction of valve tissue and the involvement of heart valves bilaterally or only on the right side are highly suggestive of NBTE<sup>5,8</sup>. Diffusion-weighted MRI makes it possible to demonstrate that patients with NBTE tend to develop multiple, widely distributed infarcts, whereas single lesions or focal infarcts are more characteristic of infective endocarditis<sup>2,5,8,9</sup>. In the present case, although there was no histopathological evidence, the absence of fever, the consistently negative blood cultures, and the lack of clinical improvement after antibiotic therapy are strongly suggestive of NBTE.</p>
      <p>Patients with cancer who develop neurological symptoms should be evaluated, and magnetic resonance imaging is the most sensitive test for detecting metastases and strokes. Using diffuse-weighed imaging (DWI), it is also possible to know if the origin of the embolus is related to infective or nonbacterial thrombotic endocarditis<sup>9</sup>.</p>
      <p>Management of NBTE consists of treatment of the underlying malignancy and systemic anticoagulation. The most effective anticoagulant in the treatment of NBTE is unfractionated heparin; when administered continuously, it reduces the risk of recurrent thromboembolism<sup>10</sup>. Recurrent thromboembolic events were observed in patients on vitamin K antagonists, but further studies are needed to confirm this association<sup>2</sup>.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Endocarditis mar&#225;ntica y adenocarcinoma de sitio primario desconocido</article-title>
      </title-group>
    </front-stub>
    <body>
      <p>
        <bold>CASO CL&#205;NICO</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Endocarditis mar&#225;ntica y adenocarcinoma de sitio primario desconocido</bold>
          </label>
          <p>
            <bold>Luis Alberto Schlittler; Viviane Weiller Dallagasperina; Claudia Schavinski; Ana Paula Baggio; N&#237;colas Silva Lazaretti; Rodrigo Ughini Villaroel</bold>
          </p>
        </fn>
      </p>
      <p>Hospital da Cidade de Passo Fundo, Passo Fundo, RS - Brasil</p>
      <p>Correspondencia</p>
      <p><bold>Palabras clave: </bold>Endocarditis, embolia y trombosis, accidente cerebrovascular, adenocarcinoma, p&#225;ncreas.</p>
      <p>La endocarditis tromb&#243;tica no bacteriana se caracteriza por el dep&#243;sito de trombos de fibrina en las v&#225;lvulas card&#237;acas normales o degenerados en ausencia de g&#233;rmenes. La patolog&#237;a se relaciona con estados inflamatorios cr&#243;nicos, con una mayor incidencia de fen&#243;menos emb&#243;licos cuando comparada a endocarditis infecciosa. Los autores refieren el caso de un paciente var&#243;n, de 63 a&#241;os con adenocarcinoma de sitio primario desconocido y la embolia sist&#233;mica.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>En 1865, Trousseau ha expuesto la asociaci&#243;n entre c&#225;ncer y tromboembolismo<sup>1</sup>. En 1988, Ziegler ha descrito la endocarditis tromb&#243;tica no bacteriana (ETNB) como deposici&#243;n de trombos y fibrina sobre valvas card&#237;acas. Estudios posteriores identificaron la relaci&#243;n entre ETNB y los estados inflamatorios cr&#243;nicos, incluyendo malignidades, septicemia y quemaduras extensas<sup>2</sup>.</p>
      <p>Los altos niveles de factor de necrosis tumoral y la interleuquina-1, presente en el c&#225;ncer, puede causar da&#241;o en el endotelio de la v&#225;lvula y la formaci&#243;n de trombos<sup>3</sup>.</p>
      <p>La incidencia de eventos emb&#243;licos es mayor que la observada en endocarditis infecciosa<sup>2</sup>. Adem&#225;s de esto, el cuadro cl&#237;nico es resultante del sitio de embolia, y es inhabitual el hallazgo de un nuevo soplo card&#237;aco.</p>
      <p>El diagn&#243;stico se realiza por la visualizaci&#243;n de una vegetaci&#243;n endoc&#225;rdica asociada con la ausencia de g&#233;rmenes en la sangre<sup>2</sup>.</p>
      <p>El manejo de la ETNB consiste en el tratamiento de la malignidad subyacente asociado con la anticoagulaci&#243;n sist&#233;mica<sup>4</sup>.</p>
      <p>Los autores relatan el caso de un paciente con adenocarcinoma de sitio primario desconocido que desarroll&#243; s&#237;ntomas neurol&#243;gicos asociados a la embolia perif&#233;rica. En la evaluaci&#243;n del origen de los &#233;mbolos, se diagnostic&#243; ETNB.</p>
      <p>
        <bold>Caso cl&#237;nico</bold>
      </p>
      <p>Paciente var&#243;n de 63 a&#241;os, refiri&#243; dolor epig&#225;strico en aprieto desde hace seis meses, agravada hac&#237;a cuatro d&#237;as, acompa&#241;ada de n&#225;useas, v&#243;mitos y p&#233;rdida de peso de diez quilos en los &#250;ltimos dos meses. El paciente era alcoh&#243;lico y realiz&#243; una cirug&#237;a para la implantaci&#243;n de pr&#243;tesis total de cadera hac&#237;a tres meses, sin intercurrencias.</p>
      <p>Al examen, se presentaba en buen estado general, l&#250;cido, afebril, ict&#233;rico +/4+, extremidades bien perfundidas. Examen abdominal: Espacio de traube ocupado, borde hep&#225;tico palpable en la regi&#243;n epig&#225;strica, cinco cent&#237;metros por debajo del reborde costal derecho, con consistencia endurecida y dolorosa, el bazo no era palpable. En el examen card&#237;aco: Ictus palpable en 5&#186; espacio intercostal, l&#237;nea hemiclavicular, 1,5 cm, ruidos fon&#233;ticamente normales, ritmo regular en dos tiempos, sin soplos. Dem&#225;s sistemas sin cambios.</p>
      <p><italic>Laboratorio -</italic> Hemoglobina 11,9 g/dl, hematocrito 37,1%, VCM 84,13fL; CHCM 32.08; plaquetas 500.000/mm<sup>3</sup>; leucocitos totales 15200/mm<sup>3</sup> con 35% de neutr&#243;filos 1% de bastones; Prote&#237;na C reactiva &lt; 7; sedimento urinario: bilirrubina (+); gamma glutamil transferase 128U/l, fosfatase alcalina 145 U/l, bilirrubina total 0,91mg%; bilirrubina directa 0,58 mg%, deshidrogenasa l&#225;ctica 719 U/l; dem&#225;s ex&#225;menes laboratoriales sin cambios.</p>
      <p><italic>Ultrasonido de abdomen -</italic> lesi&#243;n expansiva en el l&#243;bulo hep&#225;tico izquierdo, hipoecoide, heterog&#233;nea, con 12,3 cm de su mayor di&#225;metro. Dem&#225;s &#243;rganos con apariencia normal.</p>
      <p><italic>Tomograf&#237;a computarizada (TC) de abdomen total -</italic> Ascitis de peque&#241;o volumen, formaci&#243;n expansiva macrolobulada, de l&#237;mites imprecisos en el l&#243;bulo hep&#225;tico izquierdo, implicando los segmentos II, III y IV, que se halla hipodensa, siendo impregnada de modo heterog&#233;neo por el contraste. L&#243;bulo derecho con disminuci&#243;n del volumen, contornos dentados y densidad parenquimatosa heterog&#233;nea, adem&#225;s de m&#250;ltiples peque&#241;as &#225;reas hipodensas, esparcidas en el par&#233;nquima. Trombo intraluminal que se extiende desde la vena femoral derecha de la vena cava inferior. Dem&#225;s estructuras sin cambios.</p>
      <p>Se instituy&#243; anticoagulaci&#243;n completa con heparina no fraccionada asociados con warfarina.</p>
      <p><italic>Biopsia hep&#225;tica -</italic> Par&#233;nquima hep&#225;tico infiltrado por tejido neopl&#225;sico, constituido por acinos glandulares, revestidos por c&#233;lulas c&#250;bicas y cil&#237;ndricas, con c&#233;lulas en anillo de sello. En el an&#225;lisis inmunohistoqu&#237;mico mostr&#243; reactividad para el anti-CK7 y anti-CEA. No hubo positividad para anti-CK20, anti-CDX2, anti-TTF1, anti-CA19.9 y anti-Heppar. Se concluye de tratar de adenocarcinoma de sitio primario desconocido.</p>
      <p>En el tercer d&#237;a de internaci&#243;n el paciente pas&#243; a presentar desorientaci&#243;n y agresividad alternadas con per&#237;odos de lucidez.</p>
      <p><italic>TC de cr&#225;neo -</italic> lesiones hipodensas difusas, sin realce por el contraste, ubicadas en la sustancia blanca adyacentes a los cuernos de los ventr&#237;culos laterales, la reducci&#243;n del volumen encef&#225;lico global.</p>
      <p>En el cuadrag&#233;simo d&#237;a de internaci&#243;n el paciente desarroll&#243; cianosis tanto en la porci&#243;n distal del miembro inferior derecho, como en los dedos de su mano derecha, con un descenso de la temperatura local. (<xref ref-type="fig" rid="f1-body3">Figura 1</xref>) Debido a la ocurrencia de este cuadro en presencia de la anticoagulaci&#243;n completa, el tratamiento se mantuvo.</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf01-es.jpg"/></fig>
      <p>Se realiz&#243; un Ecocardiograma Doppler transtor&#225;cico uni y bidimensional, que evidenci&#243; v&#225;lvula a&#243;rtica engrosada con estructura ecog&#233;nica m&#243;vil, de 11 mm, compatible con vegetaci&#243;n, importante flujo regurgitante en esta v&#225;lvula, regurgitaci&#243;n mitral leve, disfunci&#243;n diast&#243;lica ventricular izquierda patr&#243;n restrictiva y dilataci&#243;n de c&#225;maras card&#237;acas. (<xref ref-type="fig" rid="f2-body3">Figura 2</xref>).</p>
      <fig id="f2-body3">
        <graphic xlink:href="1678-4170-abc-96-04-0e73-00018-gf02-es.jpg"/></fig>
      <p>Despu&#233;s del ecocardiograma, se estableci&#243; el tratamiento con gentamicina y ampicilina. Se llev&#243; a cabo seis muestras de sangre para hemocultivos automatizados con el aparato de Bactec, en diferentes sitios. No hubo desarrollo de los g&#233;rmenes en cinco d&#237;as de cultivo.</p>
      <p>El paciente no present&#243; mejora con la antibioticoterapia, y habiendo presentado necrosis de las extremidades, concomitante al desarrollo de falla ventilatoria, que evolucion&#243; de ese modo a la muerte.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La endocarditis tromb&#243;tica no bacteriana, anteriormente nombrada endocarditis mar&#225;ntica, es caracterizada por la deposici&#243;n de trombos en v&#225;lvulas card&#237;acas y ausencia de bacterias viables en la corriente sangu&#237;nea<sup>2</sup>.</p>
      <p>La incidencia es desconocida. Una serie de autopsias revelaron 10 casos en 1.640 adultos, prevalencia de 1,25% en los pacientes con c&#225;ncer y un 0,2% en la poblaci&#243;n general. En los pacientes con adenocarcinoma, principalmente adenocarcinoma de p&#225;ncreas, se observ&#243; una prevalencia mayor<sup>4</sup>. Autores refieren que las malignidades m&#225;s asociadas con ETNB son los tumores de pulm&#243;n, p&#225;ncreas, est&#243;mago y adenocarcinoma de sitio primario desconocido<sup>2</sup>.</p>
      <p>La ETNB es m&#225;s com&#250;n entre la cuarta y octava d&#233;cada de vida y no hay predilecci&#243;n por g&#233;nero. La incidencia de embolia sist&#233;mica var&#237;a del 14% al 91%<sup>4,5</sup>.</p>
      <p>Los sitios m&#225;s frecuentes de embolia arterial son el bazo, el ri&#241;&#243;n y la extremidad, pero los tipos de embolia cerebral y coronaria alerta para su diagn&#243;stico, debido a una mayor morbilidad y mortalidad que causan. Por otra parte, el d&#233;ficit neurol&#243;gicos s&#250;bito focal es la manifestaci&#243;n cl&#237;nica m&#225;s com&#250;n<sup>2</sup>.</p>
      <p>Cuando est&#225; presente, los soplos card&#237;acos son sist&#243;licos y con mayor intensidad en el borde esternal izquierdo<sup>2</sup>.</p>
      <p>Hay embolia pulmonar en el 50% de los casos, pero todos se observaron en pacientes con neoplasias avanzadas y trombofilia concomitante a la ETNB<sup>6</sup>.</p>
      <p>La ecocardiograf&#237;a transesof&#225;gica es el m&#233;todo m&#225;s sensible para el diagn&#243;stico de vegetaciones<sup>6</sup>.</p>
      <p>Las v&#225;lvulas m&#225;s afectadas en orden descendente son: v&#225;lvula a&#243;rtica, v&#225;lvula mitral y afectaci&#243;n simult&#225;nea de la v&#225;lvula a&#243;rtica y mitral. Las vegetaciones est&#225;n ubicadas en la superficie de coaptaci&#243;n de las hojas, en la porci&#243;n atrial de las v&#225;lvulas mitral y tric&#250;spide y en la porci&#243;n ventricular de las v&#225;lvulas a&#243;rtica y pulmonar, por lo general sin perjudicar la funci&#243;n valvular<sup>2,4</sup>.</p>
      <p>Algunos estudios sugieren la sinergia entre la lesi&#243;n de la v&#225;lvula, y la trombocitosis y la actividad de los factores de coagulaci&#243;n. An&#225;lisis gen&#233;ticas evidenciaron que el oncog&#233;n MET ocasiona aumento de la actividad del inhibidor del factor activador del plasmin&#243;geno tipo 1 (PAI-1) y de los genes de la ciclooxigenasa 2 (cox 2), contribuyendo a la formaci&#243;n de trombos<sup>7</sup>.</p>
      <p>La distinci&#243;n entre endocarditis tromb&#243;tica y infecciosa puede convertirse en un dilema diagn&#243;stico. Las vegetaciones en la superficie de coaptaci&#243;n sin destrucci&#243;n del tejido valvular y la afectaci&#243;n de la v&#225;lvula en el sentido bilateral o solamente del lado derecho del coraz&#243;n son muy altamente sugestivas de ETNB<sup>5, 8</sup>. En la resonancia magn&#233;tica por difusi&#243;n es posible demostrar que pacientes con ETNB tienden a desarrollar m&#250;ltiples infartos en el sistema nervioso central, ampliamente distribuidos, mientras que lesiones &#250;nicas o infartos focales son m&#225;s caracter&#237;sticos de la endocarditis infecciosa<sup>2,5,8,9</sup>. En el presente caso, aunque sin comprobaci&#243;n histopatol&#243;gica, la ausencia de fiebre, la negatividad persistente de las hemocultivos y la ausencia de mejora cl&#237;nica con la antibioticoterapia sugieren evidencias fuertes de ETNB.</p>
      <p>Los pacientes de c&#225;ncer que desarrollan s&#237;ntomas neurol&#243;gicos deben ser evaluados, y el examen de resonancia magn&#233;tica nuclear es el examen con la mayor sensibilidad para el diagn&#243;stico de met&#225;stasis y accidentes vasculares encef&#225;licos. Adem&#225;s de ello, la resonancia magn&#233;tica por difusi&#243;n es capaz de diferenciar si el origen del &#233;mbolo est&#225; ligado a la endocarditis bacteriana o a la ETNB<sup>9</sup>.</p>
      <p>El manejo de la ETNB consiste en el tratamiento de la malignidad subyacente y la anticoagulaci&#243;n sist&#233;mica<sup>4</sup>. El anticoagulante m&#225;s eficaz es la heparina no fraccionada, con la reducci&#243;n de la recurrencia de tromboembolismo cuando se utiliza en un continua<sup>10</sup>. Fen&#243;meno tromboemb&#243;licos recurrentes se observaron con el uso de antagonistas de la vitamina K, sin embargo esta asociaci&#243;n necesita de mayores estudios para la confirmaci&#243;n<sup>2</sup>.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
